경구 고분자 제제 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2033년)

Oral Macromolecular Formulation Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2033

US $ 4,995 ￦ 7,227,000

Unprintable PDF & Excel (Single User License)

PDF, Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 복사, 인쇄가 불가능합니다.

US $ 7,295 ￦ 10,555,000

PDF & Excel (Multi User License)

PDF, Excel 보고서를 동일 기업 내 5명까지 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

US $ 8,495 ￦ 12,291,000

PDF & Excel (Corporate User License)

PDF, Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

한글목차

Persistence Market Research는 이번에 세계의 경구 고분자 제제 시장에 관한 광범위한 리포트를 발행했습니다. 촉진요인·동향·기회·과제 등의 주요 시장 역학을 종합적으로 분석하고, 시장 구조에 관한 심층 인사이트를 제공하고 있습니다.

주요 인사이트

• 경구 고분자 제제 시장 규모(2024년) : 1,890만 달러
• 예측 시장 금액(2033년) : 2,920만 달러
• 세계 시장 성장률(CAGR 2024-2033년) : 5.0%

경구 고분자 제제 시장 - 리포트 범위 :

경구 고분자 제제 시장에는 고분자 치료제의 경구 투여를 가능하게 하는 다양한 기술과 방법이 포함됩니다. 단백질, 펩티드, 핵산을 포함한 고분자 의약품은 기존에는 소화관에서의 분해와 낮은 흡수율로 인해 경구 투여에 어려움을 겪었습니다. 그러나 최근 제형 기술의 발전으로 주사제와 같은 침습적인 방식에 비해 환자의 순응도가 높은 경구 투여로 전환되고 있습니다. 이 시장은 당뇨병, 종양, 면역학 등 다양한 치료 분야에 적용되고 있습니다.

시장 성장의 촉진요인:

세계 경구 고분자 제제 시장을 촉진하는 몇 가지 요인이 있습니다. 주요 촉진요인 중 하나는 환자 친화적인 약물전달 방법에 대한 수요가 증가하고 있다는 점입니다. 고분자 의약품이 만성질환 치료에 널리 사용됨에 따라 환자의 복약 순응도와 삶의 질을 개선하기 위해 주사제에서 경구제로의 전환에 대한 요구가 증가하고 있습니다. 침투 촉진제, 효소 억제제, 나노테크놀러지 등 제형 및 전달 기술의 발전으로 경구 경로에서 고분자의 안정성과 생체 이용률이 크게 개선되고 있습니다. 또한 소화관 분해와 같은 경구용 고분자 약물전달의 장벽을 극복하는 데 초점을 맞춘 연구개발 활동이 활발해지면서 시장 성장을 가속할 것으로 예상됩니다.

시장 성장 억제요인 :

유망한 성장 전망에도 불구하고 경구 고분자 제제 시장은 몇 가지 문제에 직면해 있습니다. 경구 고분자 제제의 개발 및 제조와 관련된 높은 비용은 특히 중소 제약사에게 시장 진입의 큰 장벽이 되고 있습니다. 또한 고분자 제제의 일관되고 효과적인 경구 생체 이용률을 달성하기 위한 기술적 어려움은 이러한 치료법의 보급을 제한하고 있습니다. 또한 새로운 경구용 고분자 치료제의 안전성과 유효성을 확보하기 위한 복잡한 규제 장벽도 시장 성장에 걸림돌로 작용하고 있습니다.

시장 기회 :

경구 고분자 제제 시장은 비침습적 치료 옵션에 대한 수요 증가로 인해 큰 성장 기회를 제공합니다. 나노입자 기반 캐리어 및 첨단 프로드러그 전략과 같은 혁신적인 약물전달 플랫폼의 개발은 경구용 고분자 약물전달의 한계를 극복할 수 있는 잠재적인 해결책을 제공합니다. 또한 특히 신흥 시장에서 만성질환의 확산으로 인해 의료 접근성 및 비침습적 치료에 대한 환자들의 선호도가 높아지면서 제약사들이 경구 고분자 제제를 도입할 수 있는 기회가 생겨나고 있습니다. 새로운 기술 개발을 위한 제약회사와 학계 및 연구기관과의 전략적 제휴는 이러한 기회를 활용하는 데 있으며, 매우 중요한 역할을 할 것으로 보입니다.

이 보고서에서 다룬 주요 질문

• 경구 고분자 제제 시장의 세계 성장을 가속하는 주요 요인은 무엇인가?
• 시장을 주도하고 있는 기술 및 제형 기술은 어떤 유형이 있는가?
• 기술의 발전은 경구 고분자 제제 시장 경쟁 구도에 어떤 영향을 미쳤는가?
• 경구 고분자 제제 시장의 주요 기업은 어디이며, 경쟁력을 유지하기 위해 어떤 전략을 취하고 있는가?
• 세계 경구 고분자 제제 시장의 새로운 동향과 미래 전망은?

목차

제1장 개요

제2장 시장 개요

• 시장 범위 / 분류
• 시장의 정의 / 범위 / 제한
• 포함 사항·제외 사항

제3장 주요 시장 동향

• 시장에 영향을 미치는 주요 동향
• 혁신 / 개발 동향

제4장 주요 성공 요인

• 채택 분석
• 질병 역학
• 주요 규제
• PESTEL 분석
• 주요 프로모션 전략 : 주요 기업별

제5장 시장 배경

• 거시경제 요인
• 예측 요인 - 관련성과 영향
• 시장 역학

제6장 COVID-19 위기 분석

• COVID-19와 영향 분석
  • 적응증별
  • 최종사용자별
  • 국가별
• 2022년 시장 시나리오

제7장 세계의 경구 고분자 제제 시장 수요(금액 또는 규모, 백만 달러) 분석

• 과거 시장 금액(백만 달러) 분석, 2019-2023년
• 현재 및 향후 시장 금액(백만 달러) 예측, 2024-2033년
  • 전년대비 성장 동향 분석
  • 절대액 기회 분석

제8장 세계의 경구 고분자 제제 시장 분석, 적응증별

• 서론 / 주요 조사 결과
• 과거 시장 규모(백만 달러) 분석, 적응증별, 2019-2023년
• 현재 및 향후 시장 규모(백만 달러) 분석과 예측, 적응증별, 2024-2033년
  • 염증성장질환
  • 당뇨병
  • 기타
• 시장의 매력 분석 : 적응증별

제9장 세계의 경구 고분자 제제 시장 분석, 최종사용자별

• 서론 / 주요 조사 결과
• 과거 시장 규모(백만 달러) 분석, 최종사용자별, 2019-2023년
• 현재 및 향후 시장 규모(백만 달러) 분석과 예측, 최종사용자별, 2024-2033년
  • 바이오의약품 기업
  • 학술·연구기관
• 시장의 매력 분석 : 최종사용자별

제10장 세계의 경구 고분자 제제 시장 분석, 지역별

• 서론
• 과거 시장 규모(백만 달러) 분석, 지역별, 2019-2023년
• 현재 및 향후 시장 금액(백만 달러) 분석과 예측, 2024-2033년
  • 북미
  • 라틴아메리카
  • 유럽
  • 동아시아
  • 남아시아
  • 오세아니아
  • 중동 및 아프리카(MEA)
• 시장의 매력 분석 : 지역별

제11장 북미의 경구 고분자 제제 시장 분석

제12장 라틴아메리카의 경구 고분자 제제 시장 분석

제13장 유럽의 경구 고분자 제제 시장 분석

제14장 동아시아의 경구 고분자 제제 시장 분석

제15장 남아시아의 경구 고분자 제제 시장 분석

제16장 오세아니아의 경구 고분자 제제 시장

제17장 중동 및 아프리카(MEA)의 경구 고분자 제제 시장 분석

제18장 시장 구조 분석

• 시장 분석 : 기업 계층별
• 주요 기업의 시장 점유율 분석
• 시장 입지 분석

제19장 경쟁 분석

• 경쟁 대시보드
• 경쟁 상세 정보
  • Catalent, Inc
  • Diabetology Ltd
  • UPM Pharmaceuticals

제20장 사용되는 전제 조건과 두자어

제21장 조사 방법

KSA

영문 목차

영문목차

Persistence Market Research has recently published an extensive report on the global Oral Macromolecular Formulation Market. This report offers a comprehensive analysis of the key market dynamics, including drivers, trends, opportunities, and challenges, providing deep insights into the market structure.

Key Insights:

• Oral Macromolecular Formulation Market Size (2024E): USD 18.9 Million
• Projected Market Value (2033F): USD 29.2 Million
• Global Market Growth Rate (CAGR 2024 to 2033): 5.0%

Oral Macromolecular Formulation Market - Report Scope:

The Oral Macromolecular Formulation Market encompasses a range of technologies and methods that allow for the oral delivery of large molecule therapeutics. Macromolecular drugs, which include proteins, peptides, and nucleic acids, traditionally face challenges in being delivered orally due to degradation in the gastrointestinal tract and poor absorption. However, recent advancements in formulation technologies are driving the shift toward oral administration, which improves patient compliance compared to invasive methods like injections. The market serves a wide range of therapeutic areas, including diabetes, oncology, and immunology.

Market Growth Drivers:

Several factors drive the global Oral Macromolecular Formulation Market. One of the major drivers is the increasing demand for patient-friendly drug delivery methods. As macromolecular drugs become more prevalent in treating chronic diseases, there is a growing need to transition from injectable forms to oral formulations to improve patient adherence and quality of life. Technological advancements in formulation and delivery technologies, such as permeation enhancers, enzyme inhibitors, and nanotechnology, have significantly improved the stability and bioavailability of macromolecules in the oral route. Additionally, increased research and development activities focused on overcoming the barriers to oral macromolecular drug delivery, such as gastrointestinal degradation, are expected to fuel market growth.

Market Restraints:

Despite the promising growth outlook, the Oral Macromolecular Formulation Market faces several challenges. The high costs associated with the development and manufacturing of oral macromolecular formulations pose a significant barrier to market entry, especially for smaller pharmaceutical companies. Moreover, the technical difficulties in achieving consistent and effective oral bioavailability for large molecules limit the widespread adoption of these therapies. The regulatory hurdles for approving novel oral macromolecular formulations, given the complexity of ensuring their safety and efficacy, also present challenges for market growth.

Market Opportunities:

The Oral Macromolecular Formulation Market offers significant growth opportunities due to the expanding demand for non-invasive therapeutic options. The development of innovative drug delivery platforms, such as nanoparticle-based carriers and advanced prodrug strategies, offers potential solutions for overcoming the limitations of oral macromolecular drug delivery. Additionally, the growing prevalence of chronic diseases, particularly in emerging markets, creates opportunities for pharmaceutical companies to introduce oral macromolecular formulations in regions where access to healthcare and patient preference for non-invasive treatments are driving factors. Strategic collaborations between pharmaceutical companies and academic research institutions to develop new technologies will also play a pivotal role in capitalizing on these opportunities.

Key Questions Answered in the Report:

• What are the primary factors driving the growth of the Oral Macromolecular Formulation Market globally?
• Which types of technologies and formulation techniques are leading the market?
• How are technological advancements influencing the competitive landscape of the Oral Macromolecular Formulation Market?
• Who are the key players in the Oral Macromolecular Formulation Market, and what strategies are they employing to stay competitive?
• What are the emerging trends and future prospects in the global Oral Macromolecular Formulation Market?

Competitive Intelligence and Business Strategy:

Key players in the global Oral Macromolecular Formulation Market, including Novo Nordisk, Biocon, and Oramed Pharmaceuticals, focus on innovation, strategic partnerships, and product differentiation to gain a competitive edge. Companies are investing in research and development (R&D) to create new drug delivery technologies and to enhance the stability and absorption of macromolecular drugs when administered orally. Collaborations with research institutions and technology providers facilitate the development of innovative products, while strategic mergers and acquisitions allow companies to expand their market presence. Furthermore, patient-centered approaches and efforts to educate healthcare professionals about the benefits of oral macromolecular formulations will continue to foster market growth.

Key Companies Profiled:

• Catalent, Inc
• Diabetology Ltd
• UPM Pharmaceuticals

Oral Macromolecular Formulation Market Industry Segmentation

Indication:

• Inflammatory Bowel Disorder
• Diabetes
• Others

End User:

• Biopharmaceutical Companies
• Academic and Research Institutes

Region:

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East & Africa

Table of Contents

1. Executive Summary

• 1.1. Global Market Outlook
• 1.2. Demand Side Trends
• 1.3. Supply Side Trends
• 1.4. Analysis and Recommendations

2. Market Overview

• 2.1. Market Coverage / Taxonomy
• 2.2. Market Definition / Scope / Limitations
• 2.3. Inclusions and Exclusions

3. Key Market Trends

• 3.1. Key Trends Impacting the Market
• 3.2. Innovation / Development Trends

4. Key Success Factors

• 4.1. Adoption Analysis
• 4.2. Disease Epidemiology
• 4.3. Key Regulations
• 4.4. PESTEL Analysis
• 4.5. Key Promotional Strategies, By Key Players

5. Market Background

• 5.1. Macro-Economic Factors
  • 5.1.1. Global GDP Growth Outlook
  • 5.1.2. Global Healthcare Outlook
  • 5.1.3. Global Oral Proteins and Peptides Market Outlook
• 5.2. Forecast Factors - Relevance & Impact
  • 5.2.1. Increase in R&D Spending
  • 5.2.2. Growing Disease Prevalence
  • 5.2.3. Cost of Formulations
  • 5.2.4. Growing Demand in Biopharma Firms
  • 5.2.5. Changes in Regulatory Policies
• 5.3. Market Dynamics
  • 5.3.1. Drivers
  • 5.3.2. Restraints
  • 5.3.3. Opportunity Analysis

6. COVID-19 Crisis Analysis

• 6.1. COVID-19 and Impact Analysis
  • 6.1.1. By Indication
  • 6.1.2. By End User
  • 6.1.3. By Country
• 6.2. 2022 Market Scenario

7. Global Oral Macromolecule Formulation Market Demand (in Value or Size in US$ Mn) Analysis 2019-2023 and Forecast, 2024-2033

• 7.1. Historical Market Value (US$ Mn) Analysis, 2019-2023
• 7.2. Current and Future Market Value (US$ Mn) Projections, 2024-2033
  • 7.2.1. Y-o-Y Growth Trend Analysis
  • 7.2.2. Absolute $ Opportunity Analysis

8. Global Oral Macromolecule Formulation Market Analysis 2019-2023 and Forecast 2024-2033, By Indication

• 8.1. Introduction / Key Findings
• 8.2. Historical Market Size (US$ Mn) Analysis By Indication, 2019-2023
• 8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Indication, 2024-2033
  • 8.3.1. Inflammatory Bowel Disorder
    • 8.3.1.1. Crohn's Disease
    • 8.3.1.2. Ulcerative Colitis
  • 8.3.2. Diabetes
  • 8.3.3. Others
• 8.4. Market Attractiveness Analysis By Indication

9. Global Oral Macromolecule Formulation Market Analysis 2019-2023 and Forecast 2024-2033, By End User

• 9.1. Introduction / Key Findings
• 9.2. Historical Market Size (US$ Mn) Analysis, By End User, 2019-2023
• 9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By End User, 2024-2033
  • 9.3.1. Biopharmaceutical Companies
  • 9.3.2. Academic and Research Institutes
• 9.4. Market Attractiveness Analysis By End User

10. Global Oral Macromolecule Formulation Market Analysis 2019-2023 and Forecast 2024-2033, By Region

• 10.1. Introduction
• 10.2. Historical Market Size (US$ Mn) Analysis By Region, 2019-2023
• 10.3. Current and Future Market Value (US$ Mn) Analysis and Forecast, 2024-2033
  • 10.3.1. North America
  • 10.3.2. Latin America
  • 10.3.3. Europe
  • 10.3.4. East Asia
  • 10.3.5. South Asia
  • 10.3.6. Oceania
  • 10.3.7. Middle East and Africa (MEA)
• 10.4. Market Attractiveness Analysis By Region

11. North America Oral Macromolecule Formulation Market Analysis 2019-2023 and Forecast 2024-2033

• 11.1. Introduction
• 11.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
• 11.3. Current and Future Market Value (US$ Mn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
  • 11.3.1. By Country
    • 11.3.1.1. U.S.
    • 11.3.1.2. Canada
  • 11.3.2. By Indication
  • 11.3.3. By End User
• 11.4. Market Attractiveness Analysis
  • 11.4.1. By Country
  • 11.4.2. By Indication
  • 11.4.3. By End User
• 11.5. Market Trends
• 11.6. Drivers and Restraints - Impact Analysis
• 11.7. Key Players - Intensity Mapping
• 11.8. Country Level Analysis & Forecast
  • 11.8.1. U.S. Oral Macromolecule Formulation Market Analysis
    • 11.8.1.1. Introduction
    • 11.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 11.8.1.2.1. By Indication
      • 11.8.1.2.2. By End User
  • 11.8.2. Canada Oral Macromolecule Formulation Market Analysis
    • 11.8.2.1. Introduction
    • 11.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 11.8.2.2.1. By Indication
      • 11.8.2.2.2. By End User

12. Latin America Oral Macromolecule Formulation Market Analysis 2019-2023 and Forecast 2024-2033

• 12.1. Introduction
• 12.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
• 12.3. Current and Future Market Value (US$ Mn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
  • 12.3.1. By Country
    • 12.3.1.1. Mexico
    • 12.3.1.2. Brazil
    • 12.3.1.3. Argentina
    • 12.3.1.4. Rest of Latin America
  • 12.3.2. By Indication
  • 12.3.3. By End User
• 12.4. Market Attractiveness Analysis
  • 12.4.1. By Country
  • 12.4.2. By Indication
  • 12.4.3. By End User
• 12.5. Market Trends
• 12.6. Drivers and Restraints - Impact Analysis
• 12.7. Key Players - Intensity Mapping
• 12.8. Country Level Analysis & Forecast
  • 12.8.1. Mexico Oral Macromolecule Formulation Market Analysis
    • 12.8.1.1. Introduction
    • 12.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 12.8.1.2.1. By Indication
      • 12.8.1.2.2. By End User
  • 12.8.2. Brazil Oral Macromolecule Formulation Market Analysis
    • 12.8.2.1. Introduction
    • 12.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 12.8.2.2.1. By Indication
      • 12.8.2.2.2. By End User
  • 12.8.3. Argentina Oral Macromolecule Formulation Market Analysis
    • 12.8.3.1. Introduction
    • 12.8.3.2. Market Analysis and Forecast by Market Taxonomy
      • 12.8.3.2.1. By Indication
      • 12.8.3.2.2. By End User

13. Europe Oral Macromolecule Formulation Market Analysis 2019-2023 and Forecast 2024-2033

• 13.1. Introduction
• 13.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
• 13.3. Current and Future Market Value (US$ Mn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
  • 13.3.1. By Country
    • 13.3.1.1. Germany
    • 13.3.1.2. Italy
    • 13.3.1.3. France
    • 13.3.1.4. U.K.
    • 13.3.1.5. Spain
    • 13.3.1.6. BENELUX
    • 13.3.1.7. Russia
    • 13.3.1.8. Rest of Europe
  • 13.3.2. By Indication
  • 13.3.3. By End User
• 13.4. Market Attractiveness Analysis
  • 13.4.1. By Country
  • 13.4.2. By Indication
  • 13.4.3. By End User
• 13.5. Market Trends
• 13.6. Drivers and Restraints - Impact Analysis
• 13.7. Key Players - Intensity Mapping
• 13.8. Country Level Analysis & Forecast
  • 13.8.1. Germany Oral Macromolecule Formulation Market Analysis
    • 13.8.1.1. Introduction
    • 13.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 13.8.1.2.1. By Indication
      • 13.8.1.2.2. By End User
  • 13.8.2. Italy Oral Macromolecule Formulation Market Analysis
    • 13.8.2.1. Introduction
    • 13.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 13.8.2.2.1. By Indication
      • 13.8.2.2.2. By End User
  • 13.8.3. France Oral Macromolecule Formulation Market Analysis
    • 13.8.3.1. Introduction
    • 13.8.3.2. Market Analysis and Forecast by Market Taxonomy
      • 13.8.3.2.1. By Indication
      • 13.8.3.2.2. By End User
  • 13.8.4. U.K. Oral Macromolecule Formulation Market Analysis
    • 13.8.4.1. Introduction
    • 13.8.4.2. Market Analysis and Forecast by Market Taxonomy
      • 13.8.4.2.1. By Indication
      • 13.8.4.2.2. By End User
  • 13.8.5. Spain Oral Macromolecule Formulation Market Analysis
    • 13.8.5.1. Introduction
    • 13.8.5.2. Market Analysis and Forecast by Market Taxonomy
      • 13.8.5.2.1. By Indication
      • 13.8.5.2.2. By End User
  • 13.8.6. BENELUX Oral Macromolecule Formulation Market Analysis
    • 13.8.6.1. Introduction
    • 13.8.6.2. Market Analysis and Forecast by Market Taxonomy
      • 13.8.6.2.1. By Indication
      • 13.8.6.2.2. By End User
  • 13.8.7. Russia Oral Macromolecule Formulation Market Analysis
    • 13.8.7.1. Introduction
    • 13.8.7.2. Market Analysis and Forecast by Market Taxonomy
      • 13.8.7.2.1. By Indication
      • 13.8.7.2.2. By End User

14. East Asia Oral Macromolecule Formulation Market Analysis 2019-2023 and Forecast 2024-2033

• 14.1. Introduction
• 14.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
• 14.3. Current and Future Market Value (US$ Mn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
  • 14.3.1. By Country
    • 14.3.1.1. China
    • 14.3.1.2. Japan
    • 14.3.1.3. South Korea
  • 14.3.2. By Indication
  • 14.3.3. By End User
• 14.4. Market Attractiveness Analysis
  • 14.4.1. By Country
  • 14.4.2. By Indication
  • 14.4.3. By End User
• 14.5. Market Trends
• 14.6. Drivers and Restraints - Impact Analysis
• 14.7. Key Players - Intensity Mapping
• 14.8. Country Level Analysis & Forecast
  • 14.8.1. China Oral Macromolecule Formulation Market Analysis
    • 14.8.1.1. Introduction
    • 14.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 14.8.1.2.1. By Indication
      • 14.8.1.2.2. By End User
  • 14.8.2. Japan Oral Macromolecule Formulation Market Analysis
    • 14.8.2.1. Introduction
    • 14.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 14.8.2.2.1. By Indication
      • 14.8.2.2.2. By End User
  • 14.8.3. South Korea Oral Macromolecule Formulation Market Analysis
    • 14.8.3.1. Introduction
    • 14.8.3.2. Market Analysis and Forecast by Market Taxonomy
      • 14.8.3.2.1. By Indication
      • 14.8.3.2.2. By End User

15. South Asia Oral Macromolecule Formulation Market Analysis 2019-2023 and Forecast 2024-2033

• 15.1. Introduction
• 15.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
• 15.3. Current and Future Market Value (US$ Mn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
  • 15.3.1. By Country
    • 15.3.1.1. India
    • 15.3.1.2. Indonesia
    • 15.3.1.3. Malaysia
    • 15.3.1.4. Thailand
    • 15.3.1.5. Rest of South Asia
  • 15.3.2. By Indication
  • 15.3.3. By End User
• 15.4. Market Attractiveness Analysis
  • 15.4.1. By Country
  • 15.4.2. By Indication
  • 15.4.3. By End User
• 15.5. Market Trends
• 15.6. Drivers and Restraints - Impact Analysis
• 15.7. Key Players - Intensity Mapping
• 15.8. Country Level Analysis & Forecast
  • 15.8.1. India Oral Macromolecule Formulation Market Analysis
    • 15.8.1.1. Introduction
    • 15.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 15.8.1.2.1. By Indication
      • 15.8.1.2.2. By End User
  • 15.8.2. Indonesia Oral Macromolecule Formulation Market Analysis
    • 15.8.2.1. Introduction
    • 15.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 15.8.2.2.1. By Indication
      • 15.8.2.2.2. By End User
  • 15.8.3. Malaysia Oral Macromolecule Formulation Market Analysis
    • 15.8.3.1. Introduction
    • 15.8.3.2. Market Analysis and Forecast by Market Taxonomy
      • 15.8.3.2.1. By Indication
      • 15.8.3.2.2. By End User
  • 15.8.4. Thailand Oral Macromolecule Formulation Market Analysis
    • 15.8.4.1. Introduction
    • 15.8.4.2. Market Analysis and Forecast by Market Taxonomy
      • 15.8.4.2.1. By Indication
      • 15.8.4.2.2. By End User

16. Oceania Oral Macromolecule Formulation Market 2019-2023 and Forecast 2024-2033

• 16.1. Introduction
• 16.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
• 16.3. Current and Future Market Value (US$ Mn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
  • 16.3.1. By Country
    • 16.3.1.1. Australia
    • 16.3.1.2. New Zealand
  • 16.3.2. By Indication
  • 16.3.3. By End User
• 16.4. Market Attractiveness Analysis
  • 16.4.1. By Country
  • 16.4.2. By Indication
  • 16.4.3. By End User
• 16.5. Market Trends
• 16.6. Drivers and Restraints - Impact Analysis
• 16.7. Key Players - Intensity Mapping
• 16.8. Country Level Analysis & Forecast
  • 16.8.1. Australia Oral Macromolecule Formulation Market Analysis
    • 16.8.1.1. Introduction
    • 16.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 16.8.1.2.1. By Indication
      • 16.8.1.2.2. By End User
  • 16.8.2. New Zealand Oral Macromolecule Formulation Market Analysis
    • 16.8.2.1. Introduction
    • 16.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 16.8.2.2.1. By Indication
      • 16.8.2.2.2. By End User

17. Middle East and Africa (MEA) Oral Macromolecule Formulation Market Analysis 2019-2023 and Forecast 2024-2033

• 17.1. Introduction
• 17.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
• 17.3. Current and Future Market Value (US$ Mn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
  • 17.3.1. By Country
    • 17.3.1.1. GCC Countries
    • 17.3.1.2. Turkey
    • 17.3.1.3. North Africa
    • 17.3.1.4. South Africa
    • 17.3.1.5. Rest of Middle East and Africa
  • 17.3.2. By Indication
  • 17.3.3. By End User
• 17.4. Market Attractiveness Analysis
  • 17.4.1. By Country
  • 17.4.2. By Indication
  • 17.4.3. By End User
• 17.5. Market Trends
• 17.6. Drivers and Restraints - Impact Analysis
• 17.7. Key Players - Intensity Mapping
• 17.8. Country Level Analysis & Forecast
  • 17.8.1. GCC Countries Oral Macromolecule Formulation Market Analysis
    • 17.8.1.1. Introduction
    • 17.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 17.8.1.2.1. By Indication
      • 17.8.1.2.2. By End User
  • 17.8.2. Turkey Oral Macromolecule Formulation Market Analysis
    • 17.8.2.1. Introduction
    • 17.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 17.8.2.2.1. By Indication
      • 17.8.2.2.2. By End User
  • 17.8.3. South Africa Oral Macromolecule Formulation Market Analysis
    • 17.8.3.1. Introduction
    • 17.8.3.2. Market Analysis and Forecast by Market Taxonomy
      • 17.8.3.2.1. By Indication
      • 17.8.3.2.2. By End User
  • 17.8.4. North Africa Oral Macromolecule Formulation Market Analysis
    • 17.8.4.1. Introduction
    • 17.8.4.2. Market Analysis and Forecast by Market Taxonomy
      • 17.8.4.2.1. By Indication
      • 17.8.4.2.2. By End User

18. Market Structure Analysis

• 18.1. Market Analysis by Tier of Companies
• 18.2. Market Share Analysis of Top Players
• 18.3. Market Presence Analysis

19. Competition Analysis

• 19.1. Competition Dashboard
• 19.2. Competition Deep Dive
  • 19.2.1. Catalent, Inc
    • 19.2.1.1. Overview
    • 19.2.1.2. Portfolio
    • 19.2.1.3. Sales Footprint
    • 19.2.1.4. Key Financials
    • 19.2.1.5. SWOT Analysis
    • 19.2.1.6. Strategy Overview
      • 19.2.1.6.1. Marketing Strategy
      • 19.2.1.6.2. Channel Strategy
  • 19.2.2. Diabetology Ltd
    • 19.2.2.1. Overview
    • 19.2.2.2. Portfolio
    • 19.2.2.3. Sales Footprint
    • 19.2.2.4. Key Financials
    • 19.2.2.5. SWOT Analysis
    • 19.2.2.6. Strategy Overview
      • 19.2.2.6.1. Marketing Strategy
      • 19.2.2.6.2. Channel Strategy
  • 19.2.3. UPM Pharmaceuticals
    • 19.2.3.1. Overview
    • 19.2.3.2. Portfolio
    • 19.2.3.3. Sales Footprint
    • 19.2.3.4. Key Financials
    • 19.2.3.5. SWOT Analysis
    • 19.2.3.6. Strategy Overview
      • 19.2.3.6.1. Marketing Strategy
      • 19.2.3.6.2. Channel Strategy

20. Assumptions and Acronyms Used

21. Research Methodology

관련자료